Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-α and interferon-α

Journal of Dermatological Science

Volumn 56, Issue 3, 2009, Pages 163-167

  Bergman, R ^a   Ramon, M ^a   Wildbaum, G ^b   Avitan Hersh, E ^a   Mayer, E ^a   Shemer, A ^c   Karin, N ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Atopic; Autoantibodies; CCL3; Interferon; Psoriasis; Tumor necrosis factor

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CYCLOSPORIN; ETRETINATE; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNITY; BLOOD SAMPLING; CELL ASSAY; CONTROLLED STUDY; DISEASE DURATION; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; REMISSION; ULTRAVIOLET B RADIATION;

ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNITY; CHEMOKINES; DERMATITIS, ATOPIC; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-17; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449534697     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.08.006     Document Type: Article

References (44)

1. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
2. Nickoloff B.J., and Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113 (2004) 1664-1675
3. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1373
4. Krueger J.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
5. Youssef S., Wildbaum G., Maor G., Lanir N., Gour-Lavie A., Grabie N., et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 161 (1998) 3870-3879
6. Wildbaum G., and Karin N. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther 6 (1999) 1128-1138
7. Wildbaum G., Youssef S., and Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J Immunol 165 (2000) 5860-5866
8. Youssef S., Maor G., Wildbaum G., Grabie N., Gour-Lavie A., and Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 106 (2000) 361-371
9. Salomon I., Netzer N., Wildbaum G., Schif-Zuck S., Maor G., and Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 169 (2002) 2685-2693
10. Wildbaum G., Netzer N., and Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 168 (2002) 5885-5892
11. Wildbaum G., Nahir M., Karin N., Lanir N., Gour-Lavie A., Grabie N., et al. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 19 (2003) 679-688
12. Goldberg R., Wildbaum G., Zohar Y., Maor G., and Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol 173 (2004) 1171-1178
13. Zohar Y., Wildbaum G., and Karin N. Beneficial autoimmunity participates in the regulation of rheumatoid arthritis. Front Biosci 11 (2006) 368-379
14. Feldmann M., Brennan F.M., and Maini N. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 14 (1996) 397-440
15. Hanifin J.M., and Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 92 (1980) 44-47
16. Chen L., Linsley P.S., and Hellstrom K.E. Costimulation of T cells for tumor immunity. Immunol Today 14 (1993) 483-486
17. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmactyoid predendritic cells initiate psoriasis through interferon-α production. JEM 202 (2005) 135-143
18. Eriksen K.W., Lovato P., Skov L., Krejsgaard T., Kaltoft K., Geisler C., et al. Increased sensitivity to interferon-α in psoriatic T-cells. J Invest Dermatol 125 (2005) 936-944
19. Ettehadi P., Greaves M.W., Wallach D., Aderka D., and Camp R.D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96 (1994) 146-151
20. Kirby B., Boffa M.J., Nayak N., Gallatin W.M., Martin S., and Griffiths C.E. The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis. Br J Dermatol 145 (2001) 1027-1028
21. Serwin A.B., Sokolowska M., and Chodynicka B. Soluble tumor necrosis factor α receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. Photodermatol Photoimmunol Photomed 21 (2005) 210-211
22. Griffiths C.E.M., Boffa M.J., Gallatin W.M., and Martin S. Elevated levels of circulating intercellular adhesion molecule-3 (clCAM-3) in psoriasis. Acta Derm Venereol 76 (1996) 2-5
23. Serwin A.B., and Chodynicka B. Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis. Biomarkers 12 (2007) 599-607
24. Menter A., and Griffiths C.E.M. Current and future management of psoriasis. Lancet 370 (2007) 272-284
25. Dolen J.G., and Mathur A. Undetectable interferon-alpha serum levels in a patient with atopic dermatitis. J Interferon Cytokine Res 15 (1995) 973-975
26. + plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol 114 (2004) 364-370
27. Jullien D., Nicolas J.F., Frappaz A., and Thivolet J. Alpha interferon treatment in atopic dermatitis. Acta Derm Venereol 73 (1993) 130-132
28. Torrelo A., Harto A., Sendagorta E., Czarnetzki B.M., and Ledo A. Interferon-alpha therapy in atopic dermatitis. Acta Derm Venereol 72 (1992) 370-372
29. Gruschwitz M.S., Peters K.P., Heese A., Stosiek N., Koch Hu, and Hornstein O.P. Effects of interferon-alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema. Int Arch Allergy Immunol 101 (1993) 20-30
30. Sumimoto S., Kawai M., Kasajima Y., and Hamamoto T. Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis. Arch Dis Child 67 (1992) 277-279
31. Pellegrino M., Minervini B., Musto P., Matera R., Greco A., and Checchia de Ambrosio C. Tumour necrosis factor-alpha and interleukin-1 beta. Two possible mediators of allergic inflammation. Minerva Pediatr 48 (1996) 309-312
32. Laan M.P., Koning H., Baert M.R., Oranje A.P., Buurman W.A., Savelkoul H.F., et al. Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75 in atopic children. Allergy 53 (1998) 51-58
33. Simon D., Braathen L.R., and Simon H.U. Increased lipopolysaccharide-induced tumour necrosis factor-alpha, interferon-gamma and interleukin-10 production in atopic dermatitis. Br J Dermatol 157 (2007) 583-586
34. Takahashi T., Sasaki Y., Hama K., Furue M., and Ishibashi Y. Production of Il-4, IL-2, IFN-gamma, and TNF-alpha by peripheral blood mononuclear cells of patients with atopic dermatitis. J Dermatol Sci 3 (1992) 172-180
35. Reinhold U., Pawelec G., Wehrmann W., Kukel S., Oehr P., and Kreysel H.W. Cytokine release from cultured peripheral blood mononuclear cells of patients with severe atopic dermatitis. Acta Derm Venereol 69 (1989) 497-502
36. Cassano N., Loconsole F., Coviello C., and Vena G.A. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 19 (2006) 237-240
37. Jacobi A., Antoni C., Manger B., Schuler G., and Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52 (2005) 522-526
38. Chan J.L., Davis-Reed L., and Kimball A.B. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 3 (2004) 315-318
39. Giustizieri M.L., Mascia F., Frezzolini A., De Pita O., Chinni L.M., Giannetti A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T-cell derived cytokines. J Allergy Clin Immunol 107 (2001) 871-877
40. Kaburagi Y., Shimada Y., Nagaoka T., Hasegawa M., Takehara K., and Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and cotaxin) in patients with atopic dermatitis. Arch Dermatol Res 293 (2001) 350-355
41. van Beelen A.J., Teunissen M.B.M., Kapsenberg M.L., and de Jong E.C. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 7 (2007) 374-381
42. Fitch E., Harper E., Skorcheva I., Kurtz S.E., and Blauvelt A. Pathology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9 (2007) 461-467
43. Shehadeh N., Pollack S., Wildbaum G., Zohar Y., Shafat I., Makhoul R., et al. Beneficial autoantibody response to CCL3 participates in the regulation of type 1 diabetes mellitus and services as a novel biomarker for its diagnosis. J Immunol 182 (2009) 8104-8109
44. Cameron M.J.G.A., Arreaza M., Grattan C., Meagher C., Sharif S., Burdick M.D., et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type 1 diabetes. J Immunol 165 (2000) 1102-1110